431 related articles for article (PubMed ID: 21506106)
1. Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells.
Godinho M; Meijer D; Setyono-Han B; Dorssers LC; van Agthoven T
J Cell Physiol; 2011 Jul; 226(7):1741-9. PubMed ID: 21506106
[TBL] [Abstract][Full Text] [Related]
2. Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer.
Godinho MF; Sieuwerts AM; Look MP; Meijer D; Foekens JA; Dorssers LC; van Agthoven T
Br J Cancer; 2010 Oct; 103(8):1284-91. PubMed ID: 20859285
[TBL] [Abstract][Full Text] [Related]
3. BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells.
Brinkman A; van der Flier S; Kok EM; Dorssers LC
J Natl Cancer Inst; 2000 Jan; 92(2):112-20. PubMed ID: 10639512
[TBL] [Abstract][Full Text] [Related]
4. BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.
Godinho MF; Wulfkuhle JD; Look MP; Sieuwerts AM; Sleijfer S; Foekens JA; Petricoin EF; Dorssers LC; van Agthoven T
Br J Cancer; 2012 Sep; 107(6):947-55. PubMed ID: 22892392
[TBL] [Abstract][Full Text] [Related]
5. Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines.
van Agthoven T; Godinho MF; Wulfkuhle JD; Petricoin EF; Dorssers LC
Int J Cancer; 2012 Nov; 131(9):1998-2007. PubMed ID: 22328489
[TBL] [Abstract][Full Text] [Related]
6. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
7. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Miller TW; Balko JM; Ghazoui Z; Dunbier A; Anderson H; Dowsett M; González-Angulo AM; Mills GB; Miller WR; Wu H; Shyr Y; Arteaga CL
Clin Cancer Res; 2011 Apr; 17(7):2024-34. PubMed ID: 21346144
[TBL] [Abstract][Full Text] [Related]
8. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD
Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366
[TBL] [Abstract][Full Text] [Related]
9. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA
J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808
[TBL] [Abstract][Full Text] [Related]
10. Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
Jan R; Huang M; Lewis-Wambi J
Breast Cancer Res; 2012 Nov; 14(6):R146. PubMed ID: 23151593
[TBL] [Abstract][Full Text] [Related]
11. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
12. Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response.
van Agthoven T; Sieuwerts AM; Meijer D; Meijer-van Gelder ME; van Agthoven TL; Sarwari R; Sleijfer S; Foekens JA; Dorssers LC
Endocr Relat Cancer; 2010 Mar; 17(1):215-30. PubMed ID: 19966015
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
Zhang X; Wang ZY
Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
[TBL] [Abstract][Full Text] [Related]
14. Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells.
van Agthoven T; Dorssers LC; Lehmann U; Kreipe H; Looijenga LH; Christgen M
PLoS One; 2015; 10(8):e0136845. PubMed ID: 26317614
[TBL] [Abstract][Full Text] [Related]
15. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
16. BCAR4 Expression as a Predictive Biomarker for Endocrine Therapy Resistance in Breast Cancer.
Liao M; Webster J; Coonrod EM; Weilbaecher KN; Maher CA; White NM
Clin Breast Cancer; 2024 Jun; 24(4):368-375.e2. PubMed ID: 38443227
[TBL] [Abstract][Full Text] [Related]
17. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
Long X; Fan M; Bigsby RM; Nephew KP
Mol Cancer Ther; 2008 Jul; 7(7):2096-108. PubMed ID: 18645020
[TBL] [Abstract][Full Text] [Related]
18. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
Creighton CJ; Massarweh S; Huang S; Tsimelzon A; Hilsenbeck SG; Osborne CK; Shou J; Malorni L; Schiff R
Cancer Res; 2008 Sep; 68(18):7493-501. PubMed ID: 18794137
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
20. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
